Evaluation of recombinant factor vila treatment for massive hemorrhage in patients with multiple traumas

Annals of Laboratory Medicine

Volumn 32, Issue 2, 2012, Pages 145-152

  Koh, Young Rae ^a   Cho, Suck Ju ^b   Yeom, Seok Ran ^b   Chang, Chulhun L ^a   Lee, Eun Yup ^a   Son, Han Chul ^a   Kim, Hyung Hoi ^a,b  

^a Pusan National University School of Medicine   (South Korea)

^b Pusan National University Hospital   (South Korea)

Author keywords

Clinical outcome; Mortality rate; Multiple trauma; Recombinant factor vila; Treatment cost

Indexed keywords

EID: 84859192737     PISSN: 22343806     EISSN: 22343814     Source Type: Journal    
DOI: 10.3343/alm.2012.32.2.145     Document Type: Article

References (23)

1. Miller RD. Complications ofmassive blood transfusions. Anesthesiology 1973;39:82-93.
2. Rudolph R and Boyd CR. Massive transfusion: complications and their management. South Med J 1990;83:1065-70. (Pubitemid 20294402)
3. Pike AC, Brzozowski AM., Roberts SM, Olsen OH, Persson E. Structure ofhuman factor Vila and its implications for the triggering of blood coagulation. Proc Natl Acad Sci 1999;96:8925-30. (Pubitemid 29374684)
4. Ingerslev J. Efficacy and safety ofrecombinant factor Vila in the prophylaxis of bleeding in various surgical procedures in hemophilic patients with factor VIII and factor IX inhibitors. Semin Thromb Hemost 2000;26: 425-32.
5. Franchini M. Recombinant factor Vila: areview on its clinical use. Int J Hematol 2006;83:126-38. (Pubitemid 44227958)
6. Kenet G, Walden R, Eldad A, Martinowitz U. Treatment oftraumatic bleeding with recombinant factor Vila. Lancet 1999;354:1879.
7. Goodnough LT and Shander AS. Recombinant factor Vlla: safety and efficacy. Curr Opin Hematol 2007;14:504-9. (Pubitemid 47484844)
8. Joo YM, Yeom SR, Ryu JH, Jeong JW, Kim Yl, Min MK, et al. Successful hemostasis bythe use of recombinant factor Vila in uncontrolled active hemorrhage of multiple trauma patients. J Korean Soc Emerg Med 2011;22:22-9.
9. Martinowitz U, Kenet G, Segal E, Luboshitz J, Lubetsky A, Ingerslev J, et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma 2001;51:431-8.
10. Dutton RP, Hess JR, Scalea TM. Recombinant factor Vila for control of hemorrhage: early experience in critically ill trauma patients. J Clin Anesth 2003;15:184-8. (Pubitemid 36593444)
11. Mayo A, Misgav M, Kluger Y, Greenberg R, Pauzner D, Klausner J, et al. Recombinant activated factor VII (NovoSeven) : addition to replacement therapy in acute, uncontrolled and life-threatening bleeding. Vox Sang 2004;87:34-40. (Pubitemid 39005745)
12. Goodnough LT, Lublin DM, Zhang L, Despotis G, Eby C. Transfusion medicine service policies for recombinant factor Vlla administration. Transfusion 2004;44:1325-31. (Pubitemid 39129245)
13. Loudon B and Smith MP. Recombinant factor Vila asan adjunctive therapy for patients requiring large volume transfusion: a pharmacoeconomic evaluation. Intern Med J 2005;35:463-7. (Pubitemid 41161062)
14. Grounds RM, Seebach C, Knothe C, Paluszkiewicz P, Smith TS, Kasal E, et al. Use ofrecombinant activated factor VII (Novoseven) in trauma and surgery: analysis of outcomes reported to an international registry. J Intensive Care Med 2006;21:27-39.
15. Rizoli SB, Nascimento B Jr, Osman F, Netto FS, Kiss A, Callum J, et al. Recombinant activated coagulation factor VII and bleeding trauma patients. J Trauma 2006;61:1419-25. (Pubitemid 44973312)
16. Cameron P, Philips L, Balogh Z, Joseph A, Pearce A, Parr M, et al. The use ofrecombinant activated factor VII in trauma patients: Experience from the Australian and New Zealand haemostasis registry. Injury 2007; 38:1030-8. (Pubitemid 47277405)
17. Boffard KD, Riou B, Warren B, Choong PI, Rizoli S, Rossaint R, et al. Recombinant factor Vila asadjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 2005;59:8-15.
18. Rizoli SB, Boffard KD, Riou B, Warren B, Lau P, Kluger Y, et al. Recombinant activated factor VII as an adjunctive therapy for bleeding control in severe trauma patients with coagulopathy: subgroup analysis from two randomized trials. Crit Care 2006;10:R178.
19. Martinowitz U and Michaelson M. Guidelines for the use of recombinant activated factor VII (rFVIIa) In uncontrolled bleeding: a report by the Israeli multidisciplinary rFVIIa task force. J Thromb Haemost 2005;3:640-8. (Pubitemid 41647873)
20. Vincent JL, Rossaint R, Riou B, Ozier Y, Zideman D, Spahn DR. Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding - a European perspective. Crit Care 2006; 10:R 120.
21. Klitgaard T, Tabanera y Palacios R, Boffard KD, lau PT, Warren B, Rizoli S, et al. Pharmacokinetics ofrecombinant activated factor VII in trauma patients with severe bleeding. Crit Care 2006;10:R104.
22. Yank V, Tuohy CV, Logan AC, Bravata DM, Staudenmayer K, Eisenhut R, et al. Systematic review: benefits and harms of in-hospital use of recombinant factor Vila for off-label indications. Ann Intern Med 2011;154:529-40.
23. Lin Y, Stanworth S, Birchall J, Doree C, Hyde C. Recombinant factor Vlla for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev 2011;16:CD005011.